Biogen, Eisai and Alzheimer's

Europe to review safety data for Eisai-Biogen Alzheimer's drug
The European Commission has requested its medicines regulator to consider safety information on Eisai and Biogen's Alzheimer's drug Leqembi, the agency said on Friday.
EU to Weigh New Safety Data on Biogen, Eisai Alzheimer’s Drug
European Union regulators will review new information relating to the safety of Eisai Co.’s and Biogen Inc.’s medicine for Alzheimer’s disease, providing a response after a meeting next month.
Biogen, Eisai Get FDA Nod for Leqembi IV Maintenance Dosing
Biogen and Eisai have won Food and Drug Administration approval of an intravenous maintenance dosing of their Leqembi drug for early Alzheimer's disease. The companies late Sunday said the FDA approved the maintenance dosing of once every four weeks after 18 months of the initiation phase of once every two weeks.
US FDA OKs monthly maintenance dosing for Eisai/Biogen's Alzheimer's drug
The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's Alzheimer's drug Leqembi, the companies said on Monday.
FDA Approves Once-Every-Four-Weeks Maintenance Dosing Of LEQEMBI For Early Alzheimer's Disease
Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) announced Sunday that the U.S. Food and Drug Administration has approved the
BIIB Secures FDA Nod for Monthly Maintenance Dosing of Alzheimer's Drug
Biogen BIIB announced that the FDA has approved a monthly maintenance dosing version for its intravenously (IV) administered Alzheimer's disease (AD) drug, Leqembi. Post the FDA approval, patients have the option to transition to a monthly maintenance dosing regimen of Leqembi after completing an 18-month course of biweekly infusions of the drug.
U.S. regulator OKs Eisai-Biogen Alzheimer's drug's continuous dosing
Japanese pharmaceutical company Eisai Co. and U.S. firm Biogen Inc. said Monday that a jointly developed Alzheimer's drug has been approved for continuous use for people with early stages of the disease by U.
Medscape56m
EMA to Review New Safety Data on Alzheimer’s Drug Leqembi
The reassessment of Leqembi’s safety data follows the agency’s previous recommendation of the drug for use in the EU.
Alzheimer's Scientists Reveal New Early Warning Sign
Taking too long to enter the phase of sleep in which we dream may be an early sign of Alzheimer's disease. This is the ...
News Medical on MSN15h
Alzheimer’s and Parkinson’s linked to aging brain’s failing waste disposal
New research uncovers how declining protein clearance mechanisms with age lead to Alzheimer’s, Parkinson’s, and other ...
Rolling Out1d
Alarming Alzheimer sleep study reveals new risk
Groundbreaking study uncovers the crucial link between REM sleep patterns and Alzheimer's disease, providing new insights for ...
Ozempic May Protect Against Alzheimer’s
One recent analysis found that, over the course of three years, people taking semaglutide (the compound in Ozempic and the weight loss drug Wegovy) were about 40 to 70 percent less likely to be ...
Delays in dreaming may be linked to Alzheimer's risk
Delays in dreaming might be an early warning sign of Alzheimer's disease. People who take significantly longer to enter the ...
Medscape2d
Alzheimer’s Disease: The Cholinergic Revival
A pathway once considered fundamental in Alzheimer’s disease is being studied intensely again, and may soon result in safer, ...
ASU researchers link common virus to Alzheimer’s disease
ASU’s Banner Alzheimer’s lab may have discovered a link between a common virus infection and Alzheimer's disease.
What steps to take if you are diagnosed with Alzheimer's disease
SaveHealth provides an overview of Alzheimer's disease, including treatment and coping mechanisms for those with the disease ...
Alzheimer's Research UK17m
Gavin Patterson joins Alzheimer’s Research UK as chair
Gavin Patterson joins Alzheimer's Research UK as chair. The former President and Chief Revenue Officer of Salesforce and CEO ...
Medical News Today2d
Taking longer to get to REM sleep could indicate Alzheimer's disease
A delay in getting to the rapid eye movement (REM) stage of sleep may be linked to Alzheimer's disease and related dementias, ...